Xenon Pharmaceuticals· Xenon Pharmaceuticals Inc. News Releases·· 28 天前精选重要性评分67
Xenon披露azetukalner治疗局灶性癫痫X-TOLE开放标签延展≥48个月中期分析
Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent KV7 Potassium Channel Opener, in Adults With Focal Epilepsy: ≥48-Month Interim Analysis of the Ongoing 7-Year X-TOLE Open-Label Extension
AI 导读
Xenon公布azetukalner（KV7钾通道开放剂）在成人局灶性癫痫中7年X-TOLE开放标签延展的≥48个月中期分析，评估长期安全性与疗效。具体数据未在原文披露。
研究关注
可跟踪azetukalner长期安全性及X-TOLE开放标签延展的疗效持续性，为局灶性癫痫后续开发提供参考。
正文 · 原文
Breadcrumb
- Home
- Investors
- News & Events
- Press Releases
- Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent KV7 Potassium Channel Opener, in Adults With Focal Epilepsy: ≥48-Month Interim Analysis of the Ongoing 7-Year X-TOLE Open-Label Extension
Investors
News & Events
(Common Stock)
Minimum 15 minutes delayed. Source: LSEG
Email alerts
来源：Xenon Pharmaceuticals · investor.xenon-pharma.com